Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 June 2019 | Story Leonie Bolleurs | Photo Barend Nagel
Marnus du Plooy
Marnus du Plooy, recipient of a Fulbright Scholarship, will depart for the Duke University in Durham, North Carolina, in August to complete a doctoral degree.

Marnus du Plooy will receive his master’s degree at the University of the Free State’s Winter Graduation Ceremony.

After completing his BSc degree in Microbiology, he discovered a passion for this field of research and enrolled for postgraduate studies in the Department of Microbial, Biochemical and Food Biotechnology at the UFS.

During his master’s, Du Plooy focused on the pathogenic yeasts, Cryptococcus neoformans and a related species, C. deneoformans.

Passion for science instilled at a young age

His passion for this field comes from a young age. “Both my parents were Science teachers and they instilled a love for Science in me. At school, I enjoyed the Science subjects the most and usually obtained my highest marks in these,” Du Plooy said. 

The pathogenic yeasts studied by Du Plooy, Cryptococcus neoformans and the sister species, C. deneoformans, often cause meningitis in immunocompromised individuals, such as in people living with HIV/Aids.

He pointed out: “Infection caused by these yeasts is right on the heels of TB as the second largest killer of HIV-positive patients in sub-Saharan Africa. The focus of my master’s project was to investigate new ways in which genes can be ‘switched off’ in these yeasts in order to study the role of the genes in virulence. Doing so could help to identify new drug targets for the treatment of this form of meningitis in subsequent studies.”

Expanding his international footprint

Although Du Plooy received his master’s degree from the UFS, he grabbed the opportunity to study abroad with both hands. He applied for and received a Fulbright scholarship from the Fulbright Foreign Student Programme, giving him the opportunity to study in the US.

“I did not expect to get very far with the application, as very few candidates are selected each year. I was very lucky to receive a Fulbright scholarship and an admission offer from Duke University for PhD studies in Microbiology,” said Du Plooy.

He hopes to continue with research on Cryptococcus and to contribute to improving the lives of HIV/Aids patients. “I have always been interested in pharmaceutical and medical research and noticed a need for better cryptococcal treatments, especially in sub-Saharan Africa. Cryptococcal meningitis is a neglected disease which claims more than 600 000 lives worldwide every year. The current treatment options are several decades old, with some only available in well-resourced areas.”

Du Plooy will depart for the US in August. “The duration of the degree is four to five years, where-after I will return to South Africa to apply what I have learned at home.”

News Archive

DNA sequencer launched at the UFS
2013-11-25

Dr Gansen Pillay, Deputy Chief Executive Officer of the National Research Foundation, explaining to the scholars what will be expected of them.

The University of the Free State (UFS) can now collect immensely valuable data on drug resistance in HIV/Aids and TB with the new DNA sequencer that was launched recently at the International workshop on HIV/AIDS and TB drug resistance at the Bloemfontein Campus.

The DNA sequencer will allow the Free State province to produce viral and bacterial genetic data to fight the local development of HIV/ Aids and TB drug resistance.

The HIV and TB epidemics have expanded very fast and South Africa now has the largest HIV and TB treatment programme in the world, with over 2 million patients on treatment. However, these successful treatment programmes are now being threatened by the appearance of drug resistance.

The Free State province has been at the forefront of fighting HIV drug resistance in South Africa and has one of the most advanced treatment programmes for the management of resistance strains in the country. In addition, researchers at the University of the Free State are leading partners in the Southern African Treatment and Resistance Network (SATuRN; www.bioafrica.net/saturn), a research network that has trained over 2 000 medical officers in the treatment of drug resistance strains.

The Department of Medical Microbiology and Virology in the Medical School at the UFS has partnered with the provincial department of health, the Medical Research Council (MRC) and the Delegation of the European Union to South Africa to fund a dedicated DNA sequencer machine that will be used to generate HIV and TB drug-resistance results. This new machine will enable cutting-edge research to take place, using the data in the province and, importantly, support patients with resistance strains to have access to advanced genotypic testing techniques.

“HIV drug resistance is a very serious problem in South Africa, and the recent advances in DNA testing technology allow clinicians in the province to access drug resistance testing, which enables them to manage patients appropriately who fail treatment, and use the results to cost-effectively extend and improve patients’ lives,” says Dr Cloete van Vuuren, Specialist in Infectious Diseases at the UFS’s Faculty of Health.

Dr Dominique Goedhals, pathologist from the Department of Medical Microbiology and Virology at the UFS, adds: “We have been looking forward to expanding our work with the clinicians and researchers, using DNA sequencing to shed light on the causes and consequences of drug resistance in urban and rural settings in the province.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept